Women In Cancer Metabolism 2021 2022

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.

This book explores in depth the relation between physical activity and cancer control, including primary prevention, coping with treatments, recovery after treatments, long-term survivorship, secondary prevention, and survival. The first part of the book presents the most recent research on the impact of physical activity in preventing a range of cancers. In the second part, the association between physical activity and cancer survivorship is addressed. The effects of physical activity on supportive care endpoints (e.g., quality of life, fatigue, physical functioning) and disease endpoints (e.g., biomarkers, recurrence, survival) are carefully analyzed. In addition, the determinants of physical activity in cancer survivors are discussed, and behavior change strategies for increasing physical activity in cancer survivors are appraised. The final part of the book is devoted to special topics, including the relation of physical activity to pediatric cancer survivorship and to palliative cancer care.

Over the last decade, our understanding of metabolism in the context of cancer has evolved greatly. It is now evident that altered cellular metabolism is an integral effector of tumorigenesis that is intricately intertwined with cell signaling as well as genetic and epigenetic regulation of diverse tumor programs. Recognizing the dysregulation of cellular metabolism as an important aspect of tumor function has offered new potential direction to seek clinical benefit by providing targets for the development of novel therapeutics. To-date, several small molecule inhibitors that target tumor or immune cell metabolism are being explored in active clinical trials as either preventive, stand-alone, or adjuvant therapies for various malignancies. Thus, identifying critical metabolic vulnerabilities in pre-neoplastic cells, cancer cells, and immune cells has direct and timely relevance for developing additional treatment and preventative strategies against cancer.

Targeted cancer metabolic pathway anti-cancer drugs achieved great success in malignant cancer treatment, however, inevitably the effect of almost all these drugs is compromised by the development of resistance. Given that recent evidence shows cancer cell metabolic reprogramming occurs after drug treatment, probably, there is a strong relationship between a specific target and particular metabolic pathway remodeling. Understanding the hidden fact and mechanisms under cell metabolism modulated by specific drug targets (in particular those related to precision medicine) may lead to the development of new therapeutic strategies to overcome drug resistance.